AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22242645
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid ethyl ester formulation 1 (12 g single dose)
Trial: 22242645
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid ethyl ester formulation 2 (12 g single dose)
Trial: 19840120
Drug: Rimonabant (non-reimbursed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant (non-reimbursed diet drug)
Trial: 19840120
Drug: Rimonabant (reimbursed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant (reimbursed diet drug)
Trial: 19840120
Drug: Regular contacts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular contacts with pharmaceutical sales representatives
Trial: 17464747
Drug: Test patches
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test patches (two types)
Trial: 17464747
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control patch (0.9% sodium chloride)
Trial: 17464747
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control patch (0.1% sodium lauryl sulphate)
Trial: 12141889
Drug: Entacapone therapy
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entacapone therapy
Trial: 12141889
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (levodopa)
Trial: 356247
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (Voltaren) 50 mg b.i.d.
Trial: 27696551
Drug: Pethidine hydrochloride
RxNorm normalized name: Pethidine hydrochloride
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine hydrochloride (35 mg) given i.v.
Trial: 21820163
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (176 μg/d)
Trial: 19438994
Drug: Tretinoin 0.05%
RxNorm normalized name: TRETINOIN 0.05% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.05% in a new gel formulation
Trial: 17472817
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and Simvastatin (dose ratios between 1:2 and 1:4)
Trial: 15619496
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg IV/oral every 12 hours
Trial: 15619496
Drug: Vancomycin 1
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1 g IV every 12 hours
Trial: 10322832
Drug: Busui Shengxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busui Shengxue Capsule (BSSXC)
Trial: 10322832
Drug: Busui Shengxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busui Shengxue Capsule (BSSXC) with IL‐3, IL‐6, IL‐11
Trial: 8490109
Drug: Brofaromine hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Brofaromine (DB13876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brofaromine hydrochloride 75 mg after overnight fasting
Trial: 8490109
Drug: Brofaromine hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Brofaromine (DB13876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brofaromine hydrochloride 75 mg after a fat- and protein-rich breakfast
Trial: 30748125
Drug: High-dose calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose calcium carbonate (3000 mg)
Trial: 30748125
Drug: High-dose magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose magnesium hydroxide/aluminum hydroxide (1600 mg each)
Trial: 30748125
Drug: Low-dose calcium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose calcium carbonate (1250 mg)
Trial: 30748125
Drug: Low-dose magnesium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose magnesium hydroxide/aluminum hydroxide (800 mg each)
Trial: 28763003
Drug: RTD (Ready-to-Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTD (Ready-to-Drink beverage with caffeine 200 mg, β-alanine 2.1 g, arginine nitrate 1.3 g, niacin 65 mg, folic acid 325 mcg, Vitamin B12 45 mcg)
Trial: 28763003
Drug: PLA (Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLA (Placebo beverage with 12 g of dextrose)
Trial: 21791660
Drug: AS03(A)-adjuvanted H5N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted H5N1 vaccine administered on different schedules (21 days, 14 days, 7 days apart, or same day)
Trial: 21791660
Drug: AS03(A)-adjuvanted H5N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted H5N1 vaccine administered on standard schedule (21 days apart)
Trial: 21791660
Drug: AS03(A)-adjuvanted H5N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted H5N1 vaccine administered on accelerated schedules (14 days, 7 days apart, or same day)
Trial: 17108585
Drug: Computer Reminder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer Reminder System (CRS) for antibiotics and asthma/COPD prescriptions
Trial: 17108585
Drug: Computer Reminder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer Reminder System (CRS) for cholesterol prescriptions
Trial: 7917777
Drug: Carbamazepine therapy
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine therapy
Trial: 7917777
Drug: Drug-free controls
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free controls
Trial: 20048655
Drug: Continuous interscalene
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous interscalene ropivacaine infusion (ropivacaine 0.2% 2 mL/hr with patient‐controlled 5‐mL boluses every hour)
Trial: 20048655
Drug: Continuous interscalene
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous interscalene ropivacaine infusion
Trial: 18701824
Drug: Different treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different treatment strategies
Trial: 16772285
Drug: Assisted hatching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assisted hatching (AH) with pronase 5 IU/ml for 1 min at 37 degrees C
Trial: 12361449
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of education and mattress encasement to reduce mite allergen exposure
Trial: 1096217
Drug: Cyproheptadine 4
RxNorm normalized name: cyproheptadine 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine 4 mg three times daily
Trial: 23968654
Drug: Single-bolus propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-bolus propofol (2 mg/kg) based on corrected body weight (CBW60)
Trial: 23968654
Drug: Single-bolus propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-bolus propofol (2 mg/kg) based on total body weight (TBW)
Trial: 17764003
Drug: Intra-articular bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular bupivacaine (20 ml of 0.25%)
Trial: 17764003
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 ml of 0.9% NaCl)
Trial: 9735663
Drug: Anti-TP antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-TP antibodies
Trial: 9735663
Drug: Anti-RT antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-RT antibodies
Trial: 9735663
Drug: Anti-RNase H
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-RNase H antibodies
Trial: 1089426
Drug: QX-572, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QX-572, 8 mg/kg body weight, administered as a slow intravenous infusion over 30 minutes
Trial: 1089426
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving saline, administered as a slow intravenous infusion over 30 minutes
Trial: 30764635
Drug: Interferential current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential current treatment for 30 minutes, twice a day for five days postoperatively.
Trial: 30764635
Drug: Sham interferential
RxNorm normalized name: thymol
DrugBank: Thymol (DB02513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham interferential current treatment (same pads applied without electrical stimulation).
Trial: 26077006
Drug: Rheohaemapheresis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheohaemapheresis treatment
Trial: 21694649
Drug: Nicergoline (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (15 mg/d)
Trial: 21694649
Drug: Imidapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril (5 mg/d)
Trial: 19307792
Drug: Chronic steroids
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic steroids (Control)
Trial: 16696632
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine gum plus health education (HE)
Trial: 16696632
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine gum plus motivational interviewing (MI)
Trial: 16642605
Drug: Head point-through-point
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head point-through-point electroacupuncture and oral administration of madopa
Trial: 16642605
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of madopa
Trial: 7554974
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg vaginal gemeprost
Trial: 2182615
Drug: L-tryptophan and
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan and artificial evening light
Trial: 84706
Drug: CHOP regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP regimens (cyclophosphamide, adriamycin, vincristine, and prednisone with either low-dose bleomycin or BCG by scarification)
Trial: 84706
Drug: COP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COP regimen (cyclophosphamide, vincristine, and prednisone with low-dose bleomycin)
Trial: 28722093
Drug: Wheat cellulose
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat cellulose particles (1 bag, 2 times per day) + Diosmin tablet (2 pills, 2 times per day)
Trial: 28722093
Drug: Diosmin tablet
RxNorm normalized name: diosmin Oral Tablet
DrugBank: Diosmin (DB08995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diosmin tablet (2 pills, 2 times per day)
Trial: 23798635
Drug: Aggressive parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive parenteral nutrition (APN)
Trial: 21563508
Drug: biomedical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biomedical therapy (diclofenec, methotrexate, and sulfasalazine)
Trial: 17121380
Drug: Inosine (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine (1-2 g daily, given twice)
Trial: 17121380
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment except for relapse period)
Trial: 8360128
Drug: Chlorhexidine/neomycin (Naseptin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine/neomycin (Naseptin) cream
Trial: 8360128
Drug: Mupirocin nasal
RxNorm normalized name: mupirocin Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin nasal ointment following failure with chlorhexidine/neomycin
Trial: 3019375
Drug: Cilazapril (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (all doses)
Trial: 26230741
Drug: Gabapentin 1300
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1300 mg/d
Trial: 26230741
Drug: Gabapentin 900
RxNorm normalized name: gabapentin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 900 mg/d
Trial: 26230741
Drug: Gabapentin 1300
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1300 mg/d and 900 mg/d
Trial: 24051993
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality training using Xbox Kinect and conventional occupational therapy
Trial: 19219405
Drug: SC low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC low-molecular-weight heparin (LMWH)
Trial: 19219405
Drug: SC unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC unfractionated heparin (UFH)
Trial: 16990410
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate for 24 months in addition to antihypertensive treatment
Trial: 15548851
Drug: Lansoprazole fast
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole fast disintegrating tablet (LFDT) with 150 mL of water
Trial: 15548851
Drug: Lansoprazole fast
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole fast disintegrating tablet (LFDT) without water (with saliva)
Trial: 11772907
Drug: Metformin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (up to 1,000 mg twice daily)
Trial: 7506223
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interferon-alpha 2a, administered in tapering doses thrice weekly for 1 year
Trial: 24049904
Drug: Energy supplement
RxNorm normalized name: Nutritional Supplement Oral Bar [PROTEIN FORTIFIED ENERGY SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy supplement with 200 mg of monensin added/kg of feed
Trial: 24049904
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement with 200 mg of monensin added/kg of feed
Trial: 24049904
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (energy supplement)
Trial: 24049904
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (protein supplement)
Trial: 31431084
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of patient characteristics, trauma characteristics, and knee complaints
Trial: 31431084
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of patient characteristics, trauma characteristics, knee complaints, and MR findings
Trial: 28607125
Drug: Enalapril and
RxNorm normalized name: enalapril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril and folic acid (10 mg enalapril and 0.8 mg folic acid)
Trial: 9646426
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2 g
Trial: 11098023
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (PR: n = 12; PV: n = 12; PVE: n = 13)
Trial: 3974174
Drug: Nimodipine (40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (40, 60, or 80 mg orally)
Trial: 3974174
Drug: Nimodipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (60 mg orally)
Trial: 23929827
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (ET) + manual therapy (MT)
Trial: 12790293
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (220 mg) once per day for one month
Trial: 10666180
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg per hour TFPI after a bolus of 0.0125 mg/kg (low-dose group)
Trial: 10666180
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg per hour TFPI after a bolus of 0.05 mg/kg (high-dose group)
Trial: 8877680
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine (oral formulation)
Trial: 1793783
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily for one week
Trial: 6571974
Drug: naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen sodium (275 mg, 2 tablets at first sign of menses, followed by one tablet 4 times daily for 3 days)
Trial: 30278530
Drug: Periocular triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periocular triamcinolone acetonide (TA) injection
Trial: 30278530
Drug: Anti-VEGF intravitreous
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF intravitreous injection
Trial: 22610930
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg/d)
Trial: 22610930
Drug: Amoxicillin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1000 mg/d)
Trial: 20562608
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50)
Trial: 18626047
Drug: Intravenous fluconazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluconazole, 800 mg daily for 2 weeks
Trial: 18626047
Drug: Intravenous fluconazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluconazole, 800 mg daily
Trial: 11367647
Drug: Xuefuzhuyu Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuefuzhuyu Pill (XFZYP)
Trial: 2462025
Drug: Involved field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved field irradiation (IF) plus nitrogen mustard, vincristine, procarbazine, +/‐ prednisone (MOP[P]) chemotherapy (previous results)
Trial: 21390262
Drug: Alarm (pocket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alarm (pocket electronic pill reminder carried for 6 months)
Trial: 7883291
Drug: Zinc treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc treated group (Gp B) - 45 mg elemental zinc, single daily post lunch dose
Trial: 3123538
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium therapy (active)
Trial: 3123538
Drug: Theophylline therapy
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline therapy (prior treatment)
Trial: 25287282
Drug: Supervised resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised resistance exercise twice a week during gestational weeks 14‐25
Trial: 21784350
Drug: Semagacestat (γ‐secretase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semagacestat (γ‐secretase inhibitor)
Trial: 21784350
Drug: Solanezumab (anti-Aβ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solanezumab (anti-Aβ monoclonal antibody)
Trial: 11375848
Drug: Propacetamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol (2 g IV)
Trial: 7488285
Drug: Prednisone plus
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone plus cyclophosphamide (intravenous bolus)
Trial: 7488285
Drug: Prednisone plus
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone plus cyclophosphamide (intravenous bolus) plus plasma exchanges
Trial: 2096413
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms selenium daily for 5 weeks
Trial: 31482307
Drug: L19IL2 in
RxNorm normalized name: L19IL2
DrugBank: Darleukin (DB17157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L19IL2 in combination with dacarbazine (DTIC; 1000 mg/m2 on day 1 of 21-day cycles)
Trial: 31482307
Drug: Dacarbazine (DTIC;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC; 1000 mg/m2 on day 1 of 21-day cycles)